Hypera S.A. (BVMF:HYPE3)

Market Cap	12.63B
Revenue (ttm)	7.44B
Net Income (ttm)	1.34B
Shares Out	632.70M
EPS (ttm)	2.10
PE Ratio	9.48
Forward PE	10.72
Dividend	1.17 (5.86%)
Ex-Dividend Date	Mar 28, 2025

Volume	2,557,900
Average Volume	3,250,825
Open	19.60
Previous Close	19.86
Day's Range	19.56 - 20.01
52-Week Range	16.62 - 32.36
Beta	0.34
RSI	53.86
Earnings Date	Apr 23, 2025

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 10,301
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: HYPE3

Financial Performance

In 2024, Hypera's revenue was 7.44 billion, a decrease of -5.97% compared to the previous year's 7.91 billion. Earnings were 1.33 billion, a decrease of -19.24%.